|
2023
|
Invention
|
Cd38-binding fusion protein combination therapy. Provided herein are methods of treating cancer (... |
|
|
Invention
|
Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof. Disclosed herein are modifi... |
|
|
Invention
|
Antibodies against tl1a and uses thereof.
The disclosure provides TNF-like ligand 1a (TL1a)-bind... |
|
2022
|
Invention
|
Anti-cd47 combination therapy.
The present invention provides a combination therapy for treating... |
|
|
Invention
|
Interferon alpha 2b variants.
The present invention provides a fusion polypeptide comprising a f... |
|
2019
|
Invention
|
Interferon alpha 2b variants. The present invention provides a fusion polypeptide comprising a fi... |
|
|
Invention
|
Combination of lenalidomide and polypeptide construct, and uses thereof. Methods for cancer treat... |
|
2018
|
Invention
|
Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b. Antibodies that specifically ... |
|
2017
|
Invention
|
Anti-cd47 combination therapy. The present invention provides a combination therapy for treating ... |
|
|
Invention
|
Attenuated type i ifn cd47 combination therapy. The present invention provides a combination ther... |
|
|
Invention
|
Fusions of antibodies to cd38 and attenuated interferon alpha. The present invention provides a p... |
|
2016
|
Invention
|
Antibodies against tl1a and uses thereof. The disclosure provides TNF-like ligand 1a (TL1a)-bindi... |
|
|
Invention
|
Polypeptide constructs and uses thereof.
The present invention provides a polypeptide construct ... |
|
2015
|
Invention
|
Interferon .alpha.2.beta. variants. The present invention provides a fusion polypeptide comprisin... |
|
|
Invention
|
Interferon α2b variants. The present invention provides a fusion polypeptide comprising a first d... |
|
|
Invention
|
Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constru... |
|
2014
|
Invention
|
Antibodies to cd1d.
Isolated antibodies or antigen binding portions thereof that bind to CD1d. T... |
|
2013
|
Invention
|
Humanized antibodies with anti-tumor activity. The present invention provides humanised antibodie... |
|
2012
|
Invention
|
Polypeptide constructs and uses thereof. The present invention provides a polypeptide construct c... |
|
|
Invention
|
Antibodies to cd1d. The present invention provides isolated antibodies or antigen binding portion... |
|
|
Invention
|
Antibodies against tl1a and uses thereof. The present disclosure provides TNF-like ligand 1a (TL1... |
|
2011
|
Invention
|
Modified antibody with improved half-life. The present invention relates to antibodies, immunoglo... |
|
|
Invention
|
Anti-il-23 heterodimer specific antibodies. The present disclosure provides an isolated or recomb... |
|
|
Invention
|
Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carboh... |
|
2010
|
Invention
|
Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancer. ... |
|
|
Invention
|
Treatment of cancer involving mutated kras or braf genes. The present invention provides a method... |
|
|
Invention
|
Humanised antibodies with anti-tumour activity. The present invention provides humanized antibodi... |
|
|
Invention
|
Humanised antibodies with anti-tumour activity. The present invention provides humanised antibodi... |
|
2009
|
Invention
|
Anti-il-12/il-23 antibodies. The present invention provides an antibody comprising an antigen bin... |
|
|
Invention
|
B haptens, and its use for treating cancer. b haptens and cancer cells and induces cells death. |
|
2007
|
Invention
|
Anti-cancer antibodies against lewisy and lewisb antigens.
The present invention provides a bind... |
|
|
Invention
|
Anti-cancer antibodies against lewisb and lewis antigens. The present invention provides a bindin... |
